⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783741 | 0.84 | — | — | |
| SCHEMBL1783152 | 0.80 | — | — | |
| SCHEMBL7145815 | 0.78 | — | — | |
| SCHEMBL19647330 | 0.74 | — | — | |
| SCHEMBL22421705 | 0.74 | — | — | |
| SCHEMBL1784234 | 0.73 | PTPN1 (0.33) | — | |
| SCHEMBL1781363 | 0.72 | METAP1 (0.31) | — | |
| SCHEMBL21335911 | 0.72 | — | — | |
| SCHEMBL18388018 | 0.71 | TSHR (0.35) | — | |
| SCHEMBL1782087 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4063389-A2 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | Genzyme Corporation (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-4015535-A1 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | Genzyme Corporation (US) | 2022-06-22 | — | — | EP | disclosed |